SOURCE: CryoPort, Inc.

April 19, 2005 13:48 ET

CryoPort, Inc. Retains Corbin and Company to Audit Financial Statements

BREA, CA -- (MARKET WIRE) -- April 19, 2005 -- CryoPort, Inc. (OTC: CYRX) announced today that it has retained the independent registered public accounting firm Corbin and Company, LLP to audit their financial statements for the past two fiscal years. Upon completion of the audits, currently estimated to be by May 31, 2005, CryoPort anticipates filing a Form 10SB with the Securities and Exchange Commission to become a reporting company under the Securities and Exchange Act of 1934, as amended. Thereafter, upon meeting all applicable requirements, CryoPort intends to have its stock listed on the OTC Bulletin Board.

CryoPort's CEO, Peter Berry, commented, "I am pleased to inform our shareholders that we are making progress in the process of becoming a reporting company. One of our long-term goals at CryoPort is to ultimately move the trading of our common stock to a higher exchange, such as NASDAQ or AMEX. We know that this process will take some time, but I believe we are moving in the right direction. I understand that our listing on a senior exchange will be subject to our ability to satisfy the much more stringent listing requirements, and as a matter of compliance, CryoPort makes no representations that it will be able to satisfy the applicable requirements of an exchange. However, I believe that our shareholders should be aware that we are working diligently towards that goal."

An Investor Fact Sheet for CryoPort is available via free download at: http://www.firstcapitalinvestors.com/factsheets/cryo.pdf.

About CryoPort, Inc.

CryoPort, Inc. (www.cryoport.com) develops leading-edge, proprietary, technology driven shipping and storage products for use in the global biotechnology and pharmaceutical sectors. The products developed by CryoPort are essential components of the infrastructure required for the testing and research components that make up the foundation of the pharmaceutical and biotechnology industries.

"SAFE HARBOR" NOTE:

Certain statements contained herein constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about the Company's industry, management's beliefs and certain assumptions made by management. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Since such statements involve risks and uncertainties, the actual results and performance of the Company may turn out to be materially different from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Unless otherwise required by law, the Company also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made herein; however, readers should carefully review reports or documents the Company files from time to time with the Securities and Exchange Commission.

Contact Information